




















































































































































































































































































































































































protein	 complexes	 at	 promoter	 regions	 of	 DNA.	 The	 composition	 of	 this	 transcriptional	
machinery	varies	with	cell	type	and	cell	cycle	allowing	for	differential	gene	expression	associated	
with	different	cellular	processes	and	pathways.	Central	mediators	of	transcription	are	coactivator	
proteins	 that	 form	 key	 protein-protein	 interactions	 (PPI)	 with	 DNA-bound	 transcriptional	
activators	 via	 activator	 binding	 domains	 (ABD).	 Due	 to	 the	 requirement	 of	 these	 activator-
coactivator	interactions	for	gene	expression,	dysregulation	of	both	activators	and	coactivators	is	
associated	 with	 many	 diseases	 including	 cancers,	 metabolic	 disorders,	 and	 developmental	
defects.	Thus,	there	is	great	interest	in	the	development	of	small	molecules	capable	of	targeting	
these	 dynamic	 protein	 interfaces	 in	 diseases	 linked	 to	 aberrant	 activator-coactivator	 activity.	
Activator-coactivator	interactions	are	challenging	small	molecule	targets	because	of	the	broad,	
dynamic	 surfaces	 that	mediate	 their	 interactions.	 Successful	 targeting	of	 these	PPIs	has	been	






ABD	 and	we	 trace	 the	mechanistic	 features	 of	 its	 interactions	with	 activators	 to	 other	more	
	 xii	
characterized	coactivator	ABDs	including	the	KIX	domain	of	CBP.	We	show	that	although	it	has	a	
unique	protein	 fold,	many	of	 the	mechanistic	 features	driving	AcID	 activator	 interactions	 are	
observed	in	structurally	diverse	ABDs.			
	 Med25	AcID	interacts	with	multiple	transcriptional	activators	demonstrated	to	drive	gene	
expression	 linked	 to	 multiple	 diseases	 including	 metastatic	 cancers.	 Disrupting	 these	 AcID-
activator	 complexes	 can	 lead	 to	downregulated	expression	of	 these	disease-associated	genes	
underscoring	the	potential	of	small	molecule	inhibitors	of	these	interactions.	We	demonstrate	
that	two	native	cysteines	within	the	AcID	domain	of	Med25	can	be	targeted	by	small	molecules	
and	 are	 functionally	 positioned	 such	 that	 targeting	 these	 cysteines	with	 small	molecules	 can	



























PPI	have	been	a	 classically	 challenging	drug	development	 target	because	of	 the	 large	 surface	









of	 all	 organisms.	While	 there	 are	 approximately	 20,000	 protein	 coding	 genes	 in	 the	 human	




gene	 requires	 the	 temporal	 and	 spatial	 arrangement	 of	 proteins	 bearing	 many	 different	





sequence	 allowing	 for	 the	 assembly	 of	 the	 preinitiation	 complex	 (PIC).	While	 these	 core	 PIC	
components	are	 required	 for	 the	 transcription	of	nearly	all	 genes,	 the	context	 specificity	and	
control	 of	 gene	 expression	 is	 attributable	 to	 a	 variable	 set	 of	 transcriptional	 activator	 and	
coactivator	 proteins	whose	 composition	 is	 influenced	 by	 factors	 such	 as	 cell	 cycle,	 cell	 type,	
extracellular	 stimuli,	 or	 epigenetic	 marks.	 Because	 of	 their	 central	 role	 in	 the	 recruitment	
andrganization	of	the	PIC,	activator-coactivator	protein-protein	interactions	are	essential	for	the	









	 Diseases	 can	 arise	 from	 incorrect	 regulation	 of	 chromatin,	 overexpression	 or	




	 In	many	of	 these	cases,	 the	protein-protein	 interactions	between	 transcriptional	
activators	 and	 their	 coactivator	 binding	 partners	 are	 key	 for	 propagation	 of	 the	 disease	
phenotype	and	thus	represent	valuable,	if	challenging,	sites	for	therapeutic	intervention.	
One	 important	 coactivator-mediated	 transcriptional	 pathway	 is	 the	 Wnt	 signaling	

































that	 knockdown	 of	 c-Myb	 expression	 or	mutations	 within	 the	 c-Myb	 activation	 domain	 that	







binding	 partner	 of	 c-Myb	 and	 MLL	 both	 of	 which	 drive	 expression	 of	 AML	 oncogenes.	 B.	
Downregulation	 of	 c-Myb	 expression	 inhibits	 leukemic	 transformations	 driven	 by	MLL-fusion	





In	 diseases	 resulting	 either	 from	 aberrant	 Wnt-signaling	 or	 p300-Myb-MLL	 mediated	
leukemogenesis,	blocking	activator-coactivator	interactions	results	in	cell	death	underscoring	the	
therapeutic	potential	of	 these	PPIs.	Even	 in	 the	mechanistically	defined,	KIX-Myb	system,	 the	
identification	 of	 small	 molecules	 has	 been	 challenging.	 In	 less	 defined	 activator-coactivator	









	 The	 transcriptional	preinitiation	 complex	 is	 composed	of	multiple	activator-interacting	
protein	 complexes	 required	 for	 the	 recruitment	 of	 RNA	 Pol	 II	 and	 activated	 gene	 expression	
(Table	 1.1).	 These	 coactivators	 perform	 multiple	 tasks	 including	 enzymatic	 modification	 of	
histones	and	DNA	or	scaffolding	and	recruitment	roles.	Many	of	these	coactivators	are	hubs	able	
to	 directly	 contact	multiple	 transcriptional	 activators	 bound	 at	 gene	 promoter	 and	 enhancer	
elements	integrating	these	signals	into	the	assembly	and	activity	of	the	PIC.	CBP,	and	its	paralog	
p300,	are	multidomain	proteins	 that	 interact	with	over	400	transcriptional	activators	and	can	










are	 conformationally	 dynamic	 protein	 folds	 that	 exist	 within	 all	 of	 the	 above	 mentioned	
coactivator	proteins	and	enable	interaction	with	the	multitude	of	transcriptional	activators	that	
regulate	the	expression	of	protein	coding	genes.	Despite	the	importance	of	activator-coactivator	
interactions	and	 their	demonstrated	 role	 in	disease,	 very	 few	ABDs	have	been	structurally	or	








































diverse	 group,	 many	 of	 the	 characterized	 ABDs	 are	 largely	 a-helical.	 In	 the	 KIX	 domain	 of	
CBP/p300,	 activators	 make	 critical	 contacts	 with	 residues	 on	 a-helices	 inducing	 allosteric	
rearrangement	 of	 the	 three	 helix	 bundle.
32,33
	 Additionally,	 flexible	 unstructured	 loops	 link	
secondary	structural	elements.	A	much	rarer	secondary	structural	feature	is	the	presence	of	b-
sheets	in	PC4	and	a	7-stranded	b-barrel	in	the	AcID	motif	of	AcID.34-37	The	presence	of	b-sheet	
























	 ABDs	 can	 use	 the	 same	 group	 of	 amino	 acids	 to	 interact	 with	 a	 diverse	 set	 of	




























bidentate	activation	domain.	VP16	has	two	functionally	 independent	activation	domains	 in	 its	
77-amino	 acid	 sequence	 that	 have	 been	 shown	 to	 simultaneously	 bind	 two	 discrete	 binding	
surfaces	 of	Med25	AcID.
12,37


































factor	 of	 two	 and	 by	 a	 factor	 of	 18	 over	MLL-KIX-HBZ.
52,55
	 A	 host	 of	 biochemical,	 NMR,	 and	










substates	 towards	 those	 that	 favor	 pKID	 binding.
33,56



























contribution	 to	 activator	 binding	 to	 ABDs	 and	 this	 has	 also	 been	 demonstrated	 to	 lead	 to	
significantly	 enhanced	 association	 rates.
62,63





	 While	 complex	 formation	 between	 activators	 and	 coactivators	 is	 characterized	 by	
















for	many	 transcription	 factors	 via	 a	 nuclear	 receptor	 recognition	 sequence	 (NR	Box)	 and	 the	
Activator	 Interaction	 Domain	 (AcID)	 (Fig	 1.3).	 AcID	 is	 a	 novel	 protein	 fold	 composed	 of	 a	 7-
stranded	b-barrel	 flanked	by	3	a-helices	and	flexible	 loops	that	 is	observed	 in	only	one	other	
protein,	 Prostate	 Tumor	Overexpressed	 Variant	 1	 (PTOV1).
64,65
	 The	 AcID	motif	 is	 an	 ABD	 for	










































have	 had	 great	 success	 identifying	 small-molecule	 enzyme	 inhibitors,	 the	 discovery	 of	 novel	
molecular	scaffolds	suited	to	the	 inhibition	of	PPIs	has	been	a	more	arduous	process.	Despite	
these	challenges,	the	development	of	chemical	probes	capable	of	targeting	transcriptional	PPI	
would	 have	 enormous	 potential	 as	 mechanistic	 probes	 and	 more	 importantly	 as	 novel	
therapeutics	for	the	numerous	diseases	stemming	from	dysregulated	transcription.	Advances	in	
PPI	inhibitor	development	have	come	from	enhanced	understanding	of	PPI	characteristics	and	




	 Notwithstanding	 the	 difficulty,	 extensive	 progress	 has	 been	 made	 this	 century	 in	





















































Stapled	 peptides	 have	 proven	 to	 be	 effective	 activator-coactivator	 inhibitors.	 Verdine	 and	
colleagues	identified	a	series	of	17-mer	stapled	peptides	capable	of	inhibiting	the	TCF-b-catenin	
interaction.	 These	 StAx	 peptides	 are	 cell	 permeable	 and	 inhibit	 b-catenin-mediated	
transcription.
8










KIX	has	also	 served	as	a	hub	of	active	 small	molecule	 inhibitor	 research.	The	KIX-pKID	
interaction	was	originally	screened	via	NMR	and	KG-501	was	identified	as	a	115	µM	inhibitor	of	
the	 complex	 capable	 of	 disrupting	 KID-KIX	 interactions	 in	 cells.
85
	 Sekikaic	 and	 lobaric	 acids	












Targeting	 the	KIX	domain	has	been	aided	by	 the	extensive	mechansitic	 and	 structural	
information	that	has	been	obtained	through	decades	of	study.	These	molecules,	 in	turn,	have	





























































































The	 overarching	 goal	 of	my	 research	 has	 been	 to	 identify	 small	molecules	 capable	 of	
targeting	 transcriptional	 activator-coactivator	 interactions	 as	 a	means	 of	 regaining	 control	 of	
aberrant	transcriptional	activity	in	diseased	cells.	To	that	end,	I	have	focused	on	the	structurally	
unique	AcID	domain	of	Med25	which	serves	as	a	necessary	binding	partner	of	several	disease-
associated	activators.	To	 facilitate	our	 small	molecule	discovery	efforts,	 I	have	 first	 sought	 to	
better	define	 the	mechanistic	details	 surrounding	activator-AcID	 interactions.	Because	AcID	 is	
such	a	novel	fold	we	demonstrate	the	extent	of	conservation	of	activator-coactivator	mechanistic	







































describe	work	developing	 inhibitors	of	 other	 transcriptional	 protein-protein	 interactions.	 This	
work	 has	 focused	 on	 targeting	 aspects	 of	 the	 NF-kB	 signaling	 pathway	 and	 describes	 the	




















































































































































































































































































communication	 between	 distinct	 binding	 surfaces.	 An	 ABD	 present	 only	 in	 metazoans,	 AcID	
contains	large	and	topologically	flat	activator	binding	surfaces	comprised	of	a	7-stranded	beta	
barrel	with	some	contribution	by	 flanking	helices.	Here,	we	dissect	key	mechanistic	details	of	
activator-AcID	 complexes	 and	 demonstrate	 that,	 despite	 its	 stabile	 fold,	 there	 is	 also	
heterogeneity	 in	 activator-AcID	 complex	 formation.	 Additionally,	 we	 find	 that	 there	 are	 two	
binding	surfaces	within	AcID	that	are	allosterically	linked.	Transient	kinetic	analysis	of	activator	

















network	encompassing	proteins	with	 varied	enzymatic	 and	 structural	 roles3-6.	Amongst	 these	
proteins,	 transcriptional	 coactivators	 act	 as	 linchpins	 between	 DNA-bound	 transcriptional	
activators	 and	 the	 rest	 of	 the	 transcriptional	machinery	 (Figure	 2.1).	 Coactivators	 perform	 a	
diverse	set	of	functions	and	can	exist	as	individual	proteins	such	as	CBP/P300	or	as	multiprotein	











	 The	 Mediator	 complex	 is	 a	 megadalton,	 multiprotein	 coactivator	 complex	 found	 in	
eukaryotes.	The	composition	of	Mediator	is	species-dependent,	with	21	subunits	observed	in	the	
yeast	 S.	 pombe	 and	 31	 subunits	 in	 mammals.10-12.	 Mediator	 composition	 simplifies	 in	
differentiated	cells	with	cell-type	dependent	downregulated	expression	of	 individual	subunits.	
For	example,	a	comparison	of	liver	progenitor	cells	to	fully	differentiated	hepatocytes	saw	the	
loss	 of	 several	 Mediator	 subunits	 including	 Med1,	 Med6,	 and	 Med14.13	 The	 loss	 of	 certain	
subunits	enables	more	specific	and	finely-tuned	gene	expression	in	these	cells	due	to	the	loss	of	
their	ability	 to	 interact	with	 transcription	 factors	or	coregulatory	partners	 13,14.	 	Regardless	of	
composition,	Mediator	 serves	 as	 a	 key	 conduit	 between	 DNA-associated	 activators	 and	 RNA	
Polymerase	II	(RNA	Pol	II).	As	a	key	member	of	the	transcriptional	pre-initiation	complex	(PIC),	
Mediator	makes	 extensive	 contacts	with	 RNA	 Pol	 II	 and	 plays	 a	 role	 in	 stabilizing	 chromatin	
architecture	bringing	enhancer	regions	of	genomic	DNA	into	proximity	with	their	correspondent	
promoter	region15-17.	
Many	Mediator	 subunits	 contain	ABDs	 that	enable	direct	 interaction	with	a	 variety	of	
promoter-bound	transcriptional	activators18.	The	canonical	 LxxLL	nuclear	 receptor	 recognition	
motif	 is	 found	in	both	Med1	and	Med2519,20.	Additionally,	the	KIX	domain	of	Med15	interacts	
with	a	variety	of	activators	including	Gcn4	(master	yeast	regulator)	and	Pdr1	(S.	cerevisiae	drug	




identify	 the	 protein-protein	 interaction	 network	 linking	 Mediator	 subunits	 within	 this	 larger	
structure.23,24	 The	 Cramer	 Lab	 recently	 published	 an	 elegant	 study	 combining	 x-ray	
crystallography	and	cryo-electron	microscopy	to	produce	a	3.4	Å	model	of	the	yeast	preinitiation	
complex	(PIC)	(Fig	2.2)	23.		Notably,	the	overall	structure	of	Mediator	is	quite	dynamic	and	is	highly	
influenced	 by	 interactions	with	 associated	 cofactors	 including	 CDK8	 or	 polymerase12,25,26.	 For	
example,	 human	Mediator	 undergoes	 large-scale	 structural	 rearrangement	 upon	 association	
with	RNA	Pol	II	primarily	via	extensive	contacts	between	Pol	II	and	the	Mediator	tail	module.25		
	








at	 better	 understanding	 the	 structure	 and	 biochemical	 mechanism	 of	 protein-protein	
interactions	 of	 individual	 Mediator	 subunits	 will	 enable	 efforts	 to	 identify	 small	 molecule	
modulators	or	inhibitors	that	can	alter	transcriptional	output.		
Med25	is	a	unique	Mediator	subunit	
Mediator	 subunit	25	of	 the	Mediator	complex	occurs	only	 in	higher	eukaryotes	and	 is	
ubiquitously	expressed	in	essentially	all	human	tissue	types30.	Med25	forms	direct	interactions	
with	multiple	transcription	factors	(VP16,	ERM,	ATF6a)	and	cofactors	(CBP/p300)	linking	them	to	
Mediator	 and	 the	 rest	 of	 the	 PIC31-35.	 Within	 the	 747-amino	 acid	 Med25	 are	 three	 distinct	
domains	(Figure	2.3).	The	N-terminal	von	Willebrand	factor	type-A	domain	(VWA)	links	Med25	
	
Figure	 2.3	 Med25	 is	 an	 activator	 interacting	 Mediator	 subunit	 A.	 Med25	 interacts	 with	







to	 the	 rest	 of	Mediator36.	 The	 NR	 box,	 is	 a	 5-amino	 acid	 LxxLL	 motif	 recognized	 by	 nuclear	




















The	 herpes	 simplex	 viral	 activator	 VP16	 forms	 specific	 contacts	 with	 both	 activator	
binding	sites	on	AcID	(Figure	2.5)1,2.	Upon	infection,	VP16	hijacks	the	transcriptional	apparatus	of	
host	cells	to	induce	expression	of	viral	genes.43-45	VP16	interacts	with	a	number	of	coactivator	
proteins	 complexes	 including:	 Mediator,	 CBP/P300,	 SAGA,	 SWI/SNF,	 and	 the	 general	











activation	 domains,	 VP16	 H1	 and	 H2	 respectively,	 each	 capable	 of	 independently	 activating	
transcription.	Underlined	residues	are	predicted	to	become	alpha	helical	upon	binding	to	AcID.	
	











	 The	novel	 structural	 fold	of	AcID	 relative	 to	other	ABDs	has	 left	many	open	questions	
surrounding	how	AcID-activator	complex	formation	differs	from	the	other	more	mechanistically	
defined	 activator	 binding	 domains	 like	 KIX	 or	 Taz1.	 Mechanistic	 definition	 of	 activator-AcID	
complexes	will	increase	insight	into	the	role	of	Med25	in	transcriptional	activation.	This	increased	




While	 the	 VP16-AcID	 interaction	 was	 recently	 described,	 there	 are	 many	 strucutural	
details	of	this	interaction	that	remain	unknown	including	binding	orientation	and	the	presence	
of	 allosteric	 communication	 between	 the	 two	 binding	 sites.	 To	 help	 further	 understand	 and	
clarify	the	AcID-VP16	interaction	we	utilized	1H,15N	HSQC	NMR	(Heteronuclear	Single	Quantum	





















Previous	 work	 combined	 with	 decades	 of	 functional	 studies	 indicate	 that	 the	 amino	















	 As	demonstrated	above,	VP16	L2L3	 is	a	useful	 full	VP16	TAD	surrogate.	When	titrated	
against	15N	Med25	AcID	in	an	HSQC	experiment	we	see	binding	saturation	above	2	equivalents	
which	reflects	the	high	affinity	of	this	interaction	(Fig	2.9).	While	most	residues	in	this	titration	
are	 perturbed	 along	 a	 linear	 vector,	 several	 residues,	 notably	 D529,	 showed	 different	
perturbation	 patterns	 above	 and	 below	 0.8	 equivalents	 (Figure	 2.9.C).	 This	 deviation	 from	
	
Figure	2.8	VP16	L2L3	overlays	largely	recapitulates	the	full	length	VP16	TAD-AcID	interaction	





















	 Mapping	 these	 perturbations	 to	 the	 surface	 of	 AcID	 reveal	 binding	 at	 both	 activator	
binding	 surfaces,	 H1	 and	 H2	 (Figure	 2.10).	 These	 perturbation	 patterns	 are	 consistent	 with	









	 Many	 activator	 binding	 domains,	 such	 as	 KIX,	 TAZ1,	 and	 TAZ2,	 interact	 with	multiple	
activators	using	a	shared	group	of	amino	acids.47-50	Although	ABDs	use	a	shared	set	of	amino	
acids	for	activator	binding,	it	has	been	demonstrated	that	different	activator	sequences	lead	to	





















	 As	 activator-coactivator	 interactions	 are	often	 “fuzzy”	 allowing	an	activator	 to	bind	 in	














	 Several	 studies	 have	 indicated	 that,	 when	 bound	 by	 coactivators,	 VP16	 adopts	 an	a-
helical	structure.	Milbradt	and	colleagues	demonstrated	that	the	N-terminal	TAD	of	VP16	(VP16	



















two	 native	 AcID	 cysteines,	 labeling	 experiments	 were	 conducted	 and	 labeling	 efficiency	was	
assessed	 by	 mass	 spectrometry	 (MS).	 The	 disulfide-capped	 cysteine	 VP16	 peptides	 were	
incubated	with	wt	Med25	AcID	in	the	presence	of	a	competitor	thiol,	b-mercaptoethanol	(b-ME)	
	 43	













multiple	 orientations	 one	 would	 expect	 higher	 labeling	 of	 the	 N-terminal	 cysteine	 peptides.	






of	 these	 two	cysteines	were	 tethered	by	VP16.	Site-directed	mutagenesis	 (SDM)	was	used	 to	
individually	replace	each	cysteine	with	alanine.	Alanine	substitution	was	chosen	because	it	is	a	
non-bulky,	 chemically	 inert	 side	 chain.	Each	mutant	AcID	variant	was	expressed,	purified	and	








	 Because	VP16	aH1	can	be	 tethered	 to	C506	but	not	C497,	 the	Tethering	data	 reveals	



























binding	 face.	A	possible	explanation	 for	 this	 is	 that	activators	can	bind	either	 surface	of	AcID	
which	 is	 also	 supported	 by	 the	 NMR	 titration	 of	 VP16	 L2L3	 (Fig	 2.9).	 This	 is	 illustrated	 by	
examining	the	binding	of	shorter	tracers	to	AcID.	We	looked	at	the	change	in	binding	affinity	that	















support	 to	 a	model	 where	 VP16	 can	 bind	 in	multiple	 orientations	 which	 would	 counter	 the	




















































	 While	 much	 information	 can	 be	 extracted	 from	 equilibrium	 binding	 experiments,	
stopped-flow	kinetics	is	a	highly	sensitive	technique	that	enables	the	quantification	of	individual	
kinetic	parameters	that	contribute	to	a	binding	event	between	two	proteins.	Transient	kinetics	
enable	 the	 detection	 and	 quantification	 of	 different	 bound	 states	 between	 activators	 and	
coactivators	 and	 how	 these	 states	 interconvert.	 These	 subtleties	 are	 invisible	 in	 equilibrium	








sensitive	 exhibiting	 low	 fluorescence	 in	 an	 aqueous	 environment,	 but	 becoming	 extremely	







VP16	 complex	 formation	 there	 is	 a	 fast	 initial	 bimolecular	 association	 followed	 by	 a	 slower	























leading	 to	 positive	 binding	 cooperativity	 for	 specific	 activator	 pairs	 when	 they	 form	 ternary	
complexes	involving	KIX.	This	positive	cooperativity	can	range	from	2	to	18-fold	depending	on	
which	two	activator	pairs	are	involved.	The	presence	of	the	two	activator	binding	surfaces	in	AcID	
led	us	 to	wonder	 if	 these	 two	surfaces	are	1)	 in	 communication	and	2)	able	 to	participate	 in	
positive	or	negative	cooperativity	during	ternary	complex	formation.	
	 To	 address	 this	 first	 question	 we	 tethered	 VP16	 aH1	 G450C	 to	 AcID	 at	 C506	 and	
performed	HSQC	NMR	experiments.	Interestingly,	perturbations	were	observed	both	within	the	




represents	 the	clearest	demonstration	 that	 targeting	one	site	of	AcID	can	be	used	 to	alter	or	




















homology	 and	 similar	 dissociation	 constants.	 These	 features	 of	 both	 AcID	 and	 VP16	make	 it	
difficult	to	link	experimental	outcomes	to	a	specific	binding	event.		
	
VP16	 H1	 and	 VP16	 H2	 can	 bind	 both	 faces	 of	 AcID	 to	 some	 degree.	 To	 counter	 this	
problem	we	utilized	VP16	aH1	cysteine	mutants	tethered	to	the	AcID	H1	face	in	stopped-flow	
kinetics	experiments	to	measure	binding	of	ligands	at	the	AcID	H2	face	(Figure	2.23)	A	4-DMN	









contribution	 stemming	 from	 the	 decreased	 koff.	 This	 represents	 the	 first	 example	 of	 positive	
cooperativity	occurring	between	the	AcID	binding	surfaces.	The	magnitude	of	this	reduction	in	




Figure	 2.24	 Positive	 cooperativity	 in	 VP16-AcID	 complexes	 A.	 Tethered	 VP16	 aH1	 induces	
positive	 cooperativity	 in	 VP16	aH2	binding	 as	measured	 by	 reductions	 in	 both	koff	 and	kr.	 B.	








cysteines	within	 the	H1	 face	of	AcID	enabled	us	 to	easily	probe	binding	at	 that	 location	with	
covalent	 cysteine-containing	 VP16-derived	 peptides,	 we	 still	 sought	 to	 investigate	 activator	
binding	at	the	H2	face.	 In	an	analogous	fashion	to	the	H1	studies,	a	panel	of	cysteine	mutant	
peptides	were	prepared	based	on	the	alpha	helical	portion	of	VP16	H2	(Fig	2.25).		
	 Because	 the	 H2	 face	 of	 AcID	 contains	 no	 native	 cysteines,	 we	 utilized	 site-directed	
mutagenesis	to	add	them	at	various	locations.	We	replaced	all	three	native	cysteines	with	alanine	















to	 C-terminal	 direction	wrapping	 underneath	AcID	 and	 finally	 binding	 the	H2	 face.	 The	VP16	
residue-independent	labeling	efficiency	was	quite	unusual	and	suggests	that	VP16	H2	can	bind	













NMR	 titration	 with	 VP16	 L2L3	 and	 in	 the	 covalent	 Med25-VP16	 L2L3	 complex	 the	 residues	









As	 was	 observed	 with	 the	 helix	 h1	 mutants,	 VP16	 aH2	 binds	 with	 seemingly	 little	













	 Using	 solution	 NMR	 we	 have	 demonstrated	 that	 there	 is	 significant	 conformational	
heterogeneity	in	activator-AcID	complex	formation.	AcID	contains	two	binding	sites	on	opposite	




in	 a	 distinct	 fashion	 from	 ATF6a.	 This	 heterogeneity	 suggests	 that	 stabilizing	 individual	
conformations	 of	 AcID	 via	 small-molecules	 may	 be	 a	 way	 to	 selectively	 inhibit	 individual	
activator-coactivator	interactions	while	promoting	others.		
	 60	




use	 of	 equilibrium	 binding	 experiments	 and	 these	 covalent	 complexes	 show	 that	 activator	
binding	is	more	promiscuous	than	previously	reported.		




































































































































the	 instrument	 and	 the	peptide/protein	mixture	 separated	 via	 a	Poroshell	 C8	 column	using	 a	
gradient	of	 5-100%	acetonitrile	 to	water	with	0.1%	 formic	 acid.	Data	was	 analyzed	using	 the	
Agilent	workstation	software.	Labeling	efficiency	was	determined	by	comparing	the	peak	heights	






























> = $ + * − $ ×





















Stopped-flow	 kinetic	 assays	 were	 performed	 on	 a	 Kintek	 SF-2001	 stopped-flow	 apparatus	
equipped	with	a	100-W	Xe	arc	lamp	in	two-syringe	mode.	The	4-DMN	fluorophore	was	excited	
at	 440	 nm	 and	 its	 emission	was	monitored	 at	wavelengths	 >510	 nm,	 using	 a	 long-pass	 filter	
(Corion).	All	 solutions	were	allowed	to	equilibrate	 in	 the	 instrument	 for	at	 least	5	min	before	
experiments	were	performed.	Concentrations	reported	are	after	mixing.	
	
All	 kinetic	 traces	 reported	 are	 an	 average	 of	 either	 ~80	 (association	 experiments),	 or	 ~40	







G & = G 0 + GI× 1 − "




the	 observed	 rate	 constants	 on	 Med25	 (association	 experiments)	 or	 unlabeled	 peptide	









predicted	 best	 time	 frame	 by	 preliminary	 fits	 in	 the	 Kintek	 software.	 An	 “inverted”	 series	 of	








To	 obtain	 well	 constrained	 value	 for	 kobs,2,max	 for	 calculating	 microscopic	 rate	 constants,	 we	

















































RSUU = RS9T,SUU,I + RS9T,SUU,E − RS9T,E,[8\	
	
A	 value	 for	 kr	 can	 also	 be	 easily	 resolved	 from	 this	 expression,	 by	 first	 subtracting	 the	 two	
observed	 off-rate	 constants	 and	 then	 substituting	 observable	 parameters	 and	 rearranging	
(Equation	5):	
	
RS9T,SUU,I − RS9T,SUU,E = (RSUU + RU + RY)
E − 4×RSUU×RY
= (RS9T,SUU,I + RS9T,SUU,E)




E − (RS9T,SUU,I − RS9T,SUU,E)
E












































































































































































































































	 The	 AcID	 activator	 binding	 domain	 in	 Med25	 interacts	 with	 multiple	 transcriptional	
activators	that	regulate	transcriptional	programs	involved	in	both	healthy	and	diseased-related	
cellular	processes.	As	a	result,	small	molecule	modulators	of	these	activator-AcID	protein-protein	
interactions	 would	 be	 useful	 both	 as	 probe	 molecules	 to	 dissect	 Med25-dependent	
transcriptional	pathways	and	as	potential	 therapeutic	agents.	 	Here	we	show	that	 two	native	
cysteines	within	the	AcID	domain	can	be	targeted	by	small	molecules	and	in	doing	so	modulate	
activator-AcID	binding	events.		We	screened	these	two	native	cysteines	using	the	site-directed	


















	 Med25	 is	 a	 key	 binding	 partner	 of	 several	 different	 transcriptional	 activators,	 and,	 as	
detailed	in	Chapters	1	and	2,	the	Activator	Interaction	Domain	(AcID)	is	the	motif	responsible	for	
forming	 direct	 interactions.	 One	 such	 set	 of	 activators	 is	 the	 ETV/PEA3	 subfamily	 of	 Ets	
transcription	 factors,	 comprised	of	ETV1,	ETV4	and	ERM.	ERM,	and	 likely	 the	other	ETS	PEA3	
subfamily	 members	 ETV1	 and	 ETV4,	 form	 direct	 contacts	 with	 AcID	 and	 regulate	 cellular	
differentiation	 and	 cell	 cycle	 progression.	 The	 ETV/PEA3	 (polyomavirus	 enhancer	 activator	 3)	




factor	 following	 the	 induction	 of	 cellular	 stress	 resulting	 in	 proteolytic	 cleavage	 and	 nuclear	
translocation.4-7	 And,	 as	 discussed	 in	 Chapter	 2,	 the	 viral	 transcriptional	 activator	 VP16	 uses	
complexation	 with	 Med25	 to	 turn	 on	 genes	 associated	 with	 viral	 replication.	 While	 these	
transcription	factors	and	the	contacts	they	make	through	Med25	are	essential	for	basic	cellular	




dependent	 cellular	 phenotypes.8	 ETV/PEA3	 members	 (ERM	 (ETV5),	 ETV1,	 and	 ETV4)	 are	






















activator	 complexes	 that	 drive	 aberrant	 transcription	 in	 different	 disease	 states,	 the	
development	of	selective	and	effective	chemical	probes	that	aid	the	mechanistic	dissection	of	
	 80	
Med25-activator	 complexes	 in	 vitro	 and	 in	 vivo	 will	 be	 necessary	 first	 steps.	 Site-selective	
covalent	 molecules	 are	 particularly	 attractive	 as	 mechanistic	 probes	 and	 as	 potential	
therapeutics	because	 they	offer	 the	ability	 to	 identify	molecules	 that	bind	specific	areas	on	a	






enables	 discovery	 of	 site-selective	 small	 molecules	 through	 covalent	 stabilization	 of	 low	
molecular	 weight	 fragments	 via	 reversible	 disulfide	 bond	 formation	 between	 molecule	 and	
protein.	B.	Application	of	identified	fragments.	
	









that	 stabilizes	 them	sufficiently	 to	enable	detection	via	MS	or	another	 readout.23	Historically,	




	 An	 excellent	 example	 of	 targeting	 an	 activator-coactivator	 complex	 was	 the	 use	 of	
Tethering	to	screen	the	MLL	binding	surface	of	KIX,	leading	to	the	molecule	1-10	(Table	3.1).25	
This	molecule	acts	as	an	inhibitor	of	MLL	binding,	a	molecular	co-chaperone	capable	of	stabilizing	
the	 KIX	 domain,	 and	 stabilized	 the	 fold	 sufficiently	 for	 the	 first	 crystal	 structure	 of	 the	 KIX	




























































































































cells	 while	 inhibiting	 or	 preventing	 AcID	 interactions	 with	 disease-associated	 activators.	 This	
approach	offers	the	chance	to	be	less	disruptive	to	transcriptional	regulation	at	large,	with	only	
the	 desired	 activator-AcID	 complexes	 being	 inhibited.	 This	 can	 only	 be	 achieved	 through	













more	 onerous.	 The	 presence	 of	 native	 cysteines	 in	Med25	 expedites	 the	 process	 of	moving	










cysteines	 through	 alkylation	 with	 iodoacetamide	 probes.30,31	 Before	 initiating	 a	 screening	






	 Med25	 AcID	 contains	 three	 native	 cysteines,	 two	 of	which	 are	 located	within	 the	 H1	
binding	surface	of	AcID	(Figure	3.2).	Based	on	published	NMR	structures,	the	thiol	side	chains	of	
C497	and	C506	project	outwards	 towards	solvent.	Cysteine	429	projects	 inwards	 towards	 the	
center	of	the	beta-barrel	making	 it	 less	 likely	to	be	accessible	to	a	covalent	small	molecule.	A	
suitable	cysteine	would	be	both	reactive	with	small	molecules	and	positioned	such	that	when	






























































inhibition	 or	 otherwise	 perturb	 AcID-activator	 complex	 formation.	 In	 addition	 to	 finding	
inhibitors	 of	 activator-AcID	 complexes,	 compounds	 capable	 of	 stabilizing	 or	 inducing	 discrete	


















	 Traditional	 Tethering	 screening	 utilizes	 mass	 spectrometry	 to	 detect	 interacting	
fragments.	While	 this	 gives	 important	 information	 about	 fragment	 binding,	 it	 does	 not	 give	
information	 about	 the	 inhibitory	 activity	 of	 each	 fragment.	 Fluorescence	 polarization	 (FP)	
Tethering	screens	first	measure	the	ability	of	each	fragment	to	inhibit	binding	of	a	fluorescently-









Because	ERM	was	 inhibited	by	4-iodoacetamidosalicylic	acid	 to	 the	 largest	degree	 (Fig	





different	 b-ME	 concentrations	 acted	 as	 a	 stringency	 filter	 by	 outcompeting	 fragments	 only	
weakly	captured	by	Med25	(Fig	3.6).		
	 After	 screening	 the	 1600	 compound	Wells	 library,	 the	 31	most	 effective	 inhibitors	 (%	
inhibition	 >	 3	 standard	 deviations	 above	 the	mean)	were	 carried	 forward	 to	 determine	 their	
extent	of	covalent	labeling.	Both	the	FP	screen	and	the	MS	analysis	were	performed	at	three	b-
ME	 concentrations.	 Because	 disulfide	 bond	 formation	 is	 reversible,	 increasing	 b-ME	






some	of	 the	most	 effective	 labelers	 of	AcID	were	 comparatively	weak	 inhibitors	 (Figure	 3.8).	











Figure	3.8	 FP	Tethering	Results	 ranked	by	 labeling	efficiency	 Top	 compounds	 from	screen	 ranked	by	
highest	single	labeling	percentage	at	0.2	mM	b-ME.	Highest	inhibition	is	indicated	in	green	progressively	














Figure	 3.9	 Tethering	 screen	 identifies	 fragments	 with	 unique	 properties	 and	 diverse	 structure	 FP	





Despite	 the	 low	molecular	weight	 (~400	Da),	 several	distinct	molecular	 scaffolds	were	
identified	(Fig	3.9).	The	molecules	that	possessed	high	levels	of	both	labeling	and	inhibition	all	
contained	a	nipecotic	acid	moiety	appended	to	some	other	variable	chemical	moiety	indicating	




binding.	 To	 effectively	 study	 the	 effect	 A6	 had	 on	 activator	 binding	 and	 AcID	 structure	 it	 is	
necessary	to	 isolate	AcID	fully	 labeled	with	small	molecule	at	either	of	 the	reactive	cysteines.	
















	 Disulfide	 bonds	 are	 readily	 reduced	 in	 the	 reducing	 environment	 of	 the	 cell.	 Thus,	
molecules	 identified	 via	 Tethering	 must	 be	 modified	 before	 they	 can	 be	 utilized	 as	 cellular	
probes.	Replacement	of	the	disulfide	moiety	with	an	electrophilic	alkylating	group	enables	these	
fragments	to	be	turned	into	irreversible	probes	that	can	be	used	as	cellular	probes.		






	 A6	 iodoacetamide	was	surprising	 in	 is	selectivity.	As	we	have	demonstrated,	C497	and	




	 In	 Chapter	 2	 we	 showed	 that	 Med25	 AcID	 displays	 significant	 heterogeneity	 in	 the	





















acid	 3-fluorotyrosine.34	 An	 advantage	 of	 PrOF	 NMR	 is	 that	 one	 is	 monitoring	 side	 chain	
perturbations	rather	than	perturbations	to	the	amide	backbone	as	is	done	in	HSQC	experiments	



























from	AcID,	was	not	 impacted	by	A6.	However,	 the	 rate	 corresponding	 to	 the	 conformational	
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as	 a	 therapeutic	 target.	 The	 transcriptional	 activator	ATF6a	 is	 an	endoplasmic	 reticulum	 (ER)	
associated	 activator	 that	 is	 activated	 by	 cellular	 stress	 and	 the	 accumulation	 of	 misfolded	
proteins	 at	 the	 ER.	 Under	 stress	 conditions	 ATF6a	 translocates	 to	 the	 nucleus	 and	 activates	






treatment	with	 thapsigargin	 leading	 to	 elevated	 HSPA5	 expression	 and	 gene	 expression	was	
measured	 by	 RT-qPCR.37	 Treatment	 with	 A6	 iodoacetamide	 resulted	 in	 dose-dependent	
inhibition	of	HSPA5	demonstrating	 that	 targeting	 the	ATF6a-Med25	 interaction	with	covalent	
molecules	is	a	viable	method	of	altering	Med25	mediated	transcription	(Fig	3.15.B).	
	
Figure	 3.15	 Inhibiton	 of	 ATF6a-Med25	mediated	 gene	 expression	 by	 A6	 iodoacetamide	 A.	
HSPA5	 expression	 is	mediated	 by	 an	 ATF6a	 interaction	with	Med25	 via	 the	 AcID	 domain.	 B.	
Thapsigargin	induces	ER-associated	stress	leading	to	the	activation	and	translocation	of	ATF6a	











programs	 through	 interactions	 with	 a	 diverse	 group	 of	 transcriptional	 activators.	 The	 AcID	
activator	 binding	 domain	 of	Med25	 has	 been	 observed	 in	 only	 one	 other	 protein,	 PTOV1,	 in	





and	 when	 alkylated	 by	 4-iodoacetamidosalicylic	 acid,	 activator	 binding	 is	 inhibited	 which	
demonstrates	that	these	cysteines	are	positioned	in	functionally	relevant	locations.		
	 These	results	motivated	us	to	use	the	site-specific	Tethering	screening	strategy	to	identify	
covalent	 small	 molecule	 modulators	 of	 AcID.	 In	 a	 screen	 of	 1600	 molecules,	 we	 identified	
molecules	that	inhibited	ERM	binding	and	covalently	labeled	AcID.	Conversion	of	one	of	these	
hits,	A6,	from	a	disulfide	to	an	irreversible	iodoacetamide	alkylator	enabled	homogenous	labeling	
of	AcID.	A6	 iodoacetamide	 induced	perturbations	 in	AcID	 at	 the	 site	 of	 alkylation	 and	 at	 the	
opposite	H2	binding	face	of	AcID	suggesting	that	it	can	engage	the	same	conformational	change	
network	that	the	covalent	VP16	peptides	could	access	in	Chapter	2.	Further,	A6	iodoacetamide	











from	 Prof.	 Patrick	 Cramer.38	 Modified	 pAcID	 constructs	 were	 prepared	 using	 site	 directed	
mutagenesis	as	previously	described.32	
Protein	expression		
























































was	 analyzed	 using	 the	 Agilent	workstation	 software.	 Labeling	 efficiency	was	 determined	 by	
comparing	the	peak	heights	of	mass	adducts	corresponding	to	Med25,	Med25	+	1	alkylation,	and	
Med25	+	2	alkylation	using	the	following	equation:	




























































described	 to	 estimate	HSPA5	mRNA	 levels	 relative	 to	 the	 reference	 RPL19	mRNA	 levels.	 The	






































































































































while	 leaving	 the	 non-canonical	 pathway	 unperturbed.	 We	 also	 mechanistically	 define	 the	
activity	of	the	recently	reported	ketogibberellic	acid	methyl	ester	small	molecule	that	displays	

















complex	 network	 of	 protein-protein	 interactions.	 While	 activator-coactivator	 protein-protein	
























as	activators	of	gene	expression.4	p50	and	p52	 lack	TADs	and	 instead	have	a	 large	c-terminal	
region	composed	of	ankyrin	repeats	that	is	proteolytically	cleaved	to	form	active	p50	and	p52.	
The	lack	of	a	TAD	in	either	p50	or	p52	is	consistent	with	their	role	as	repressors	of	transcription.5	
The	 five	 family	 members	 are	 capable	 of	 forming	 15	 possible	 homo-	 and	 heterodimers	 that	
produce	distinct	 transcriptional	outputs.	 	Homo-	and	heterodimers	 composed	of	at	 least	one	





contain	 transcriptional	 activation	 domains,	 which	 p100/p52	 and	 p105/p50	 lack.	 Instead,	




cytosol	NF-kBs	are	 sequestered	by	 Inhibitor	of	kB	 (IkBs)	which	block	 the	nuclear	 localization	
sequences	 of	 RelA,	 RelB,	 and	 c-Rel.6	 Uncleaved	 p50	 and	 p52	 (p105	 and	 p100,	 respectively)	
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and	 IKKb,	 and	 a	 regulatory	 domain	 NEMO	 (NF-kB	 essential	 modifier).	 The	 IKK	 complex	











inhibitors	 targeting	 these	 interfaces	 challenging.	 11,12	 	 	 NF-kB	 activation	 is	 dependent	 on	 the	
coordinated	interplay	of	many	protein-protein	interactions.	Targeting	these	PPI	offer	a	means	of	













components	 of	 the	 pathway	 assemble	 and	 operate	 only	 in	 specific-contexts	 making	 them	







rest	 of	 the	 TNF	 receptor	 complex	 enabling	 phosphorylation	 of	 IKKs	 via	 TAK1	 kinase.9	
Phosphorylation	activates	 IKKa	 and	 IKKb	 enabling	 them	 to	phosphorylate	and	 inactivate	 IkBs	
sequestering	NF-kB	dimers	in	the	cytosol	thus	freeing	them	to	translocate	to	the	nucleus.			









IKK	 complex	 assembly.	 IKKs	 form	 critical	 contacts	with	 two	 tryptophans.	B.	 The	NBD	 sequence	 of	 IKK	






6	 amino	 acid	 sequence	 containing	 two	 hot	 spot	 tryptophans	 that	 are	 positioned	 by	 an	
intramolecular	 hydrogen	 bond	 between	D738	 and	 S740	 (Fig	 4.3.b)	 forming	 a	 loop	 lacking	a-
helicity	or	b-sheet	character.17	Given	the	importance	of	these	tryptophans	in	mediating	this	PPI,	
we	hypothesized	 that	 further	 stabilization	of	 this	 loop	by	 replacement	of	 the	hydrogen	bond	
bridge	with	a	non-labile	connection	may	increase	potency	and	stability	of	this	NBD	peptide	as	a	
cellular	inhibitor	of	the	IKK-NEMO	interaction.		
	 Substitution	of	D738	and	D740	with	allylglycine	enabled	 replacement	of	 the	hydrogen	
bond	 loop	 with	 a	 4-carbon	 synthetic	 loop	 via	 ring	 closing	 metathesis	 (Fig	 4.4).22	 Molecular	
dynamics	simulations	of	wild	type	NBD	and	NBD	stabilized	by	a	c-c	bond	(NBD2,	Fig	4.5.a)	reveal	
similar		key	dihedral	angles	indicating	that	this	modification	preserves	key	NBD	loop	geometry.23	
This	modification	did	not	 significantly	alter	 the	 secondary	 structure	of	 the	peptide	as	 circular	
dichroism	spectra	of	 the	modified	peptide	compare	 favorably	 to	wild	 type	NBD.	Significantly,	














Figure	 4.5	 Cellular	 activity	 of	modified	NBD	 peptides	 A.	 NBD	 peptides	were	 composed	 of	 a	
octalysine	 cell	 penetrating	 peptide	 (CPP),	 a	 diglycine	 linker	 (GG),	 and	 variations	 of	 the	 NBD	
sequence.	B.	 Inhibition	of	 IL-1b	 induced	NF-kB-driven	 luciferase	activity	by	NBD	constructs	 in	
HeLa	 cells.	 Performed	by	Paul	Bruno.	Modified	 from	Bruno	et	 al.	Angew.	Chem.	 Int.	 Ed.	2016.	 55,	
14997-15001.	
	
















unperturbed.	Unlike	 the	canonical	pathway,	non-canonical	NF-kB	activation	 is	driven	 through	
IKKa	homodimerization.	The	IKKa	homodimer	is	phosphorylated	by	NIK	in	response	to	a	cellular	
signal	leading	to	phosphorylation	of	cytosol-sequestered	NF-kB	dimers	(Fig	4.7).	Critically,	this	














	 Thus,	 NBD2	 is	 a	 selective	 inhibitor	 of	 canonical	 NF-kB	 signaling.	 Because	 of	 the	
considerable	 cross-talk	 in	NF-kB	 and	 the	 function	of	 individual	 subunits	 in	 different	 signaling	
pathways,	a	chemical	probe	capable	of	acting	specifically	on	an	individual	pathway	is	valuable.	
The	use	of	this	synthetic	 loop	replacement	strategy	increased	the	potency	and	stability	of	the	
NBD	 peptide	 by	 a	 factor	 of	 10.	 The	 success	 of	 this	 peptide	 points	 to	 the	 utility	 in	 targeting	
transcriptional	PPI	beyond	activator-coactivator	interactions.		
	 	






















Annand	 and	 colleagues	 demonstrated	 that	 derivatives	 of	 gibberellic	 acid	 potently	
inhibited	an	NF-kB-driven	luciferase	reporter	assay	(Fig	4.9)34.	While	pharbinilic	acid	was	inactive	
in	 this	 assay,	 the	 conversion	 of	 free	 carboxylic	 acids	 to	 methyl	 esters	 increased	 its	 activity.	
Alternatively,	converting	the	carboxylic	acid	of	gibberellic	acid	to	a	methyl	ester	did	not	enhance	
activity.	 Oxidation	 of	 the	 secondary	 alcohol	 on	 gibberellic	 acid	methyl	 ester	 (GAme)	 to	 form	
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in	 uncovering	 the	mechanism	by	which	 it	 acted	 on	 the	NF-kB	 pathway	 and	 in	 identifying	 its	
protein	binding	partners.	The	oxidation	of	the	secondary	alcohol	to	the	ketone	formed	an	a,b	
unsaturated	 carbonyl	 which	 are	 known	 cysteine-targeting	 electrophiles.	 Thus,	 the	 enhanced	
activity	 of	 kGAme	 could	 be	 due	 to	 it	 now	 acting	 through	 a	 covalent	mechanism.	 To	 identify	
protein	 binding	 partners,	 a	 biotinylated	 variant	 of	 kGAme	 was	 prepared	 (Fig	 4.10).	 This	
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neutravidin.35,36	This	 tight	 interaction	enables	pull-down	of	biotinylated	proteins	 from	cellular	
lysate	via	beads	coated	in	immobilized	neutravidin.	Neutravidin	will	also	pull	down	biotinylated	
small	 molecules	 and,	 by	 extension,	 proteins	 that	 have	 affinity	 for	 the	 active	 moiety	 of	 the	
biotinylated	compound.37	Our	pull-down	involved	treatment	of	HeLa	lysate	pre-stimulated	with	
IL-1b	 to	 induce	NF-kB	activity	followed	by	exposure	to	magnetic	neutravidin-beads.	Following	







IL-1b	 followed	by	 lysis	 to	which	 the	biotinylated	probe	was	 added.	After	 incubation	 to	 allow	
molecule	engagement	with	cellular	targets,	lysate	was	incubated	with	neutravidin-coated	beads.	









result	 would	 indicate	 that	 kGAme	 is	 targeting	 a	 location	 outside	 of	 this	 sequence.	 It	 is	 also	
possible	that	p65,	RelB	and	c-Rel	are	being	pulled	down	as	part	of	a	larger	protein	complex	and	
thus	 are	 not	 true	 binding	 targets	 of	 kGAme.	 Efforts	 to	 probe	 pulled-down	 lysate	 with	 a	
streptavidin-HRP	conjugate	to	detect	the	presence	of	the	biotinylated	molecule	bound	to	p65,	











or	 simply	 interacted	with	multiple	 NF-kB	 components,	 we	 probed	 for	 NF-kB	 subunits	 in	 the	








signaling,	we	wondered	 if	 kGAme	might	 target	 the	 IKK-NEMO	 complex,	 inactivate	 the	 kinase	
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activity	of	the	IKKs,	or	inhibit	NF-kB	activity	in	some	fashion	that	would	otherwise	disrupt	nuclear	







allowing	for	NF-kb	 translocation	to	the	nucleus	whereupon	 it	 is	 then	rapidly	shuttled	out	and	
bound	again	by	IkB.6,38	Nuclear	translocation	of	p65	and	c-Rel	were	not	inhibited	by	kGAme,	but	
translocation	 of	 IKKa	 was	 significantly	 attenuated.	 These	 results	 were	 confirmed	 by	
immunofluorescence	microscopy.	 IL-1b	 stimulated	 nuclear	 transclocation	 of	 p65	 of	 and	 IKKa	
whereas	treatment	with	kGAme	inhibited	translocation	of	IKKa,	but	not	p65	(Fig	4.14).		







Figure	 4.13	 kGAme	 inhibits	 nuclear	 translocation	 HeLa	 cells	 treated	 with	 DMSO,	 GAme	
(inactive),	and	kGAme	(active)	followed	by	stimulation	via	IL-1b.	Cell	lysate	was	fractionated	into	
























non-canonical	 and	 other	 alternate	 functions	 of	 NF-kB	 intact.	 An	 analysis	 of	 protein-protein	




activity.	We	 have	 shown	 that	 it	 does	 interact	 with	 core	 NF-kB	 transcription	 factors	 and	 the	











Peptides	 used	 in	 this	 studyAll	 peptides	 were	 synthesized	 on	 CLEAR	 amide	 resin	 (Peptides	
International)	 using	 standard	 HBTU/HOBT/DIEA	 solid	 phase	 peptide	 synthesis	 protocols	 as	
previously	described.44	The	TFA-	cleaved	peptides	were	precipitated	with	chilled	diethyl	ether,	








a	dry,	 degassed	 solution	of	 0.4	M	LiCl	 in	DMF.	 The	 resin	was	allowed	 to	 swell	with	 the	DMF	
solution	for	1	hour	at	which	point	a	solution	of	Hoveyda-Grubbs	Generation	II	catalyst	(20	mol%)	
in	dry	dichloromethane	(0.5	mL)	was	added	to	the	swollen	resin.	The	vessel	containing	the	resin	
and	 catalyst	 was	 inserted	 in	 the	microwave	 reactor	 (Biotage	 Initiator)	 and	 radiated	 (varying	
power)	for	15	minutes	at	a	constant	temperature	of	100	°C.	After	the	resin	had	been	subjected	
to	microwave	irradiation,	the	reaction	mixture	was	transferred	to	a	manual	peptide	synthesizer	
vessel	 and	washed	 3x	with	 dichloromethane	 and	 3x	with	 dimethylformamide	 to	 remove	 any	






pBSSK	 were	 generously	 provided	 by	 Dr.	 Jorge	 Iñigues-Lluhí	 (The	 University	 of	 Michigan	






manufacturer’s	 instructions.	After	4.5h,	 transfection	solution	was	 removed	and	replaced	with	
DMEM	 containing	 10%	 FBS.	 After	 24h,	 cells	 were	 trysinized	 and	 resuspended	 in	 DMEM	
supplemented	with	10%	FBS	and	seeded	into	a	96-well	plate	at	a	density	of	8x103	cells	per	well.	
After	 16h,	 media	 was	 removed	 and	 supplemented	 with	 Opti-Mem	 containing	 vehicle,	 SLR	





























described	 to	 estimate	MIP3α	mRNA	 levels	 relative	 to	 the	 reference	 RPL19	mRNA	 levels.	 The	
reported	mean	and	standard	deviation	 for	MIP3α	and	 IL-8	expression	were	determined	using	
three	 technical	 replicates	 from	 one	 representative	 biological	 replicate.47,48	 Three	 biological	
replicates	 were	 performed.	 The	 reported	 mean	 and	 standard	 deviation	 for	 Cyclin	 D1	 were	











4	 °C	 for	 20	minutes.	Next,	 100	µL	 lysate	was	 treated	with	DMSO,	 kGAB,	 or	 inactive	 reduced	
biotinylated	gibberellic	acid	(GAB)	to	a	final	concentration	of	15	µM	and	allowed	to	mix	in	1.5	mL	

















treated	with	 DMSO,	 15	µM	kGAme,	 or	 15	µM	GAme	 in	Opti-mem	 for	 1	 hr.	 Cells	were	 then	













































































































































































	 Transcriptional	 activation	 hinges	 on	 the	 arrangement	 and	 coordination	 of	 dozens	 of	
proteins	to	accurately	transcribe	the	genetic	material	required	for	healthy	cellular	function.	This	
complex	protein-protein	 interaction	network	 can	accurately	 integrate	 cellular	 signals	 into	 the	
recruitment	and	assembly	of	the	transcriptional	machinery	at	the	appropriate	locations	on	DNA	
to	 express	 genes	 relevant	 to	 that	 specific	 cellular	 process.	 Critical	 hubs	 in	 these	 activation	
pathways	 are	 transcriptional	 coactivators.	 Coactivators	 are	 linchpins	 between	 DNA-bound	
transcriptional	 activators	 and	 the	 rest	 of	 the	 preinitiation	 complex	 necessary	 for	 gene	
expression.1,2	 Transcriptional	 activation	 can	 become	 dysregulated	 through	 many	 different	
avenues	including	overexpression,	chromosomal	translocations,	and	mutations	to	the	activator	
itself	or	one	of	its	key	regulatory	partners.	As	such,	therapeutic	targeting	of	the	protein-protein	
interactions	 (PPI)	 between	 activators	 and	 coactivators	 represent	 a	 promising	 strategy	 for	
correcting	aberrant	transcriptional	activity	in	a	variety	of	diseases	ranging	from	developmental	
disorders	to	cancers	to	metabolic	diseases.3	These	PPI	are		historically	challenging	small	molecule	
targets	because	of	 the	 large	surface	area	and	structural	plasticity	 that	are	hallmarks	 to	many	
activator-coactivator	interactions.4,5	As	a	result,	successful	targeting	of	these	PPI	depend	on	the	
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use	 of	 novel	 small	 molecule	 discovery	 strategies	 coupled	 with	 studies	 that	 enhance	 our	
mechanistic	understanding	of	individual	activator-coactivator	interactions.		
	 In	this	work,	we	have	sought	to	mechanistically	define	activator	binding	to	the	Activator	




the	 AcID	 domain,	 including	 activators	 that	 display	 AcID-dependent	 expression	 of	 genes	
implicated	 in	 a	 number	 of	 different	 diseases	 including	 many	 cancers.7,8	 As	 such,	 molecules	
capable	of	modulating	these	protein	interactions	have	potential	therapeutic	utility.	In	order	to	
guide	our	small	molecule	development	efforts,	we	first	sought	to	define	mechanistic	details	of	





were	many	 outstanding	 questions	 surrounding	 the	 interactions	 of	 these	 activators	with	AcID	









by	 each	 activator	 sequence.	 This	 conformational	 heterogeneity	 is	 similar	 to	 the	 distinct	
complexes	observed	with	different	activators	bound	to	 the	same	binding	site	on	KIX.11,12	This	
suggests	that	it	may	be	possible	to	selectively	inhibit	binding	of	one	activator	while	preserving	
the	 binding	 ability	 of	 another	 activator	 by	 using	 a	 small	 molecule	 capable	 of	 inducing	 and	
stabilizing	individual	conformations	of	AcID.			

















faces	 of	 AcID	 to	 some	 degree.	 As	 the	 length	 of	 the	 tethered	 VP16	 construct	 was	 increased,	
inhibition	of	 activator	 binding	 to	both	 faces	of	AcID	 increased,	which	 suggested	 that	 as	 both	
binding	surfaces	of	AcID	were	progressively	occluded	by	the	tethered	peptide,	this	promiscuous	
dual	site	binding	behavior	was	reduced.	
	 	Transient	 kinetic	 analysis	 of	 activator	 binding	 can	 reveal	 discrete	 kinetic	 parameters	
guiding	 activator-coactivator	 complex	 formation	 that	 are	 invisible	 to	 equilibrium	 binding	








change	 network	 linking	 the	 two	 surfaces	 that	 can	 be	 accessed	 by	 transcriptional	 activators.		
When	this	tethered	VP16	aH1-AcID	complex	was	used	in	dissociation	kinetics	experiments,	a	20%	




	 Taken	 together,	 the	 data	 revealed	 that	 although	 Med25	 AcID	 has	 a	 very	 different	
structure	 from	 other	 characterized	 ABDs,	 certain	 mechanistic	 features	 are	 conserved	 across	
domains.	Like	other	ABDs,	AcID	displays	conformational	heterogeneity	when	bound	to	activators	
of	 divergent	 sequences.	 There	 is	 also	 a	 communication	 network	 that	 links	 the	 two	 binding	
surfaces	of	AcID,	promoting	positive	cooperativity	 in	activator	binding	similar	 to	activator-KIX	











and	 ERM	binding.	 The	 presence	 of	 both	 hydrophobicity	 from	 the	 benzyl	 group	 and	 negative	






targeting	 adaptable	 protein-protein	 interfaces.18,19	We	 utilized	 an	 FP-based	 tethering	 format	
whereby	we	 first	 assessed	 the	 ability	 of	 each	molecule	 in	 the	 library	 to	 inhibit	 ERM	 binding	
followed	by	a	 secondary	 screen	 to	assess	 the	degree	of	 covalent	 labeling	of	 the	most	potent	
inhibitors.	 This	 format	 identified	molecules	 that	were	effective	 inhibitors	of	 ERM	binding	but	




compound	 targeted	 C506	 on	 AcID,	 but	 was	 unable	 to	 fully	 label	 AcID	 while	 still	 a	 disulfide.	








	 Targeting	 activator-coactivator	 interactions	 is	 a	 challenge.	 Transcriptional	 activation	 is	






unrelated	 signaling	 cascades.	 The	 development	 of	 a	 potent	 cell-active	 probe	 capable	 of	
selectively	inhibiting	a	single	NF-kB	signaling	pathway	would	be	a	valuable	mechanistic	probe.	
	 Canonical	 NF-kB	 signaling	 is	 activated	 by	 the	 heterotetrameric	 IKK	 kinase	 complex.	





hydrogen	bond	stabilized	 loop	 in	 the	NEMO	binding	domain	with	a	carbon-carbon	bond.	This	
synthetic	 loop	 replacement	 variant	 of	 the	NBD	peptide	 is	 10	 times	more	potent	 than	 a	 non-
stabilized	NBD	peptide	and	is	resistant	to	proteolytic	degradation.	Importantly,	we	show	that	the	


























to	 AcID	 we	 saw	 that	 it	 did	 induce	 structural	 perturbations	 and	 binding	 cooperativity	 at	 the	
opposite	binding	surface.	We	think	we	are	more	likely	to	find	molecules	that	can	capture	and	
stabilize	unique	conformations	of	AcID	if	we	use	labeling-efficiency	as	our	primary	read	out.		





of	both	ERM	and	VP16	and	thus	 identifying	molecules	 that	specifically	 target	C497	 instead	of	
C506	would	be	useful.	To	identify	compounds	capable	of	targeting	this	site,	we	will	be	conducting	








	 In	 collaboration	 with	 the	Wells	 Lab	 at	 UCSF	 1600	 compounds	 were	 screened	 against	
Med25	and	 tethering	efficiency	was	determined	via	MS.	 Initially,	Med25	was	screened	 in	 the	
presence	of	100	equivalents	of	each	disulfide	and	1000	equivalents	of	b-mercaptoethanol	(1	µM	
Med25,	100	µM	molecule,	1	mM	b-ME).	Based	on	this	initial	screen,	24	fragments	were	identified	
that	 had	 labeling	 efficiencies	 greater	 than	 3	 standard	 deviations	 above	 the	 mean	 labeling	
efficiency	(15	%	labeled).	These	24	compounds	were	then	validated	by	screening	against	Med25	
at	100	µM	b-ME	followed	by	screening	against	Med25	C506A	at	100	µM	b-ME	(Fig	5.1).	



































in	pull-down	experiments	 to	verify	 that	Med25	 is	 targeted.	This	can	be	 further	confirmed	via	
proteomics	 to	 assay	 the	 proteome-wide	 binding	 profile	 of	 these	 covalent	 molecules.	 More	
significantly,	 we	 are	 interested	 in	 the	 ability	 of	 these	 molecules	 to	 inhibit	 PEA3-dependent	
expression	of	cancer	associated	genes	including	the	matrix	metalloproteinases	MMP-1,	MMP-2,	






functional	 consequences	 of	 allosteric	 changes	 induced	 in	 the	 H2	 face	 via	 small	 molecules	
targeting	the	H1	face	of	AcID.28-30		 	
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